Oncolytics Biotech Inc T.ONC

Astellas acquires retinal disease company for US$5.9 Billion

[Noteable]

Iveric Biotechnology retinal disease product Avacincaptad pegol is in the midst of a FDA review for approval.

https://endpts.com/astellas-to-buy-iveric-bio-for-5-9b-in-cash-as-biotech-awaits-august-fda-nod-in-retinal-disease/

[jimsenior]

@Noteable. Incyte scrapping; have not looked at it yet; please assess. TIA

[jimsenior]

PS. I was quite certain IRENE was OK, and it is, but should have ckecked before posting.  later

[Noteable]

Incyte cull is self-explanatory in the following link ... Incyte is whittling down its R&D pipeline, scrapping six discovery programs—one in a rare form of anemia and five in various cancers—to focus on eight remaining programs. The company has ended work n a small molecule PI3K inhibitor. Incyte has also ended development of its adenosine program, which includes four separate

[jimsenior]

From the Incyte article  -  "The pipeline trim will allow the pharma to funnel its resources to programs that can have a high impact for patients and for Incyte."

[jimsenior]

The Incyte IRENE trial is  Phase 2 TNBC with an Estimated Primary Completion Date of June 30, 2023.

[Noteable]

Incyte's business development activites have all been "small potatoes". Nothing to speak about. https://en.wikipedia.org/wiki/Incyte

[jimsenior]

@Noteable. Yes. But a quick look tells us 2021 Revenue was 2.99B USD. They have friends including Medicxi. I have thought and still think they will be a part of the ONC/Y story. IRENE has been a slow and steady TNBC trial, and was not run for fun. Time will tell.

[jimsenior]

A further look tells us Incyte's 2022 Revenue was 3.395B USD. A nice increase over 2022. One never knows with some small potatoes. A well traded stock today our ONC/Y Best.

[jimsenior]

Why I think Incyte's IRENE mTNBC is interesting. Second & Third Line  -  Retifanlimab & Pela. Incyte & Roche are not strangers. Roche's AWARE-1  -   TNBC patients  -  Atezolizumab & Pela.  Perhaps we are looking at a possible triplet. PD-L1 & PD-1 & Pela. The above are just a layman's idle thoughts.

[jimsenior]

Clarification - The TNBC patients in AWARE-1 are in Cohort 3.

[Noteable]

Medicixi is a "small potatoes" investment firm whose business is to accumulate a portfolio of start-up companies that it then licenses out or sells to Big Pharma. Not what ONCY would want at this time in ONCY's life cycle. https://www.businesswire.com/news/home/20221003005269/en/Incyte-Announces-Agreement-to-Acquire-Medicxi-backed-Villaris-Therapeutics-and-Auremolimab-VM6-an-Anti-IL